Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 174

1.

An RNA toolbox for cancer immunotherapy.

Pastor F, Berraondo P, Etxeberria I, Frederick J, Sahin U, Gilboa E, Melero I.

Nat Rev Drug Discov. 2018 Sep 7. doi: 10.1038/nrd.2018.132. [Epub ahead of print] Review.

PMID:
30190565
2.

Hapten-mediated recruitment of polyclonal antibodies to tumors engenders antitumor immunity.

Schrand B, Clark E, Levay A, Capote AR, Martinez O, Brenneman R, Castro I, Gilboa E.

Nat Commun. 2018 Aug 22;9(1):3348. doi: 10.1038/s41467-018-05566-x.

3.

NFκB in Pancreatic Stellate Cells Reduces Infiltration of Tumors by Cytotoxic T Cells and Killing of Cancer Cells, via Up-regulation of CXCL12.

Garg B, Giri B, Modi S, Sethi V, Castro I, Umland O, Ban Y, Lavania S, Dawra R, Banerjee S, Vickers S, Merchant NB, Chen SX, Gilboa E, Ramakrishnan S, Saluja A, Dudeja V.

Gastroenterology. 2018 Sep;155(3):880-891.e8. doi: 10.1053/j.gastro.2018.05.051. Epub 2018 Jul 29.

PMID:
29909021
4.

Potentiating tumor immunity using aptamer-targeted RNAi to render CD8+ T cells resistant to TGFβ inhibition.

Puplampu-Dove Y, Gefen T, Rajagopalan A, Muheramagic D, Schrand B, Gilboa E.

Oncoimmunology. 2018 Feb 15;7(4):e1349588. doi: 10.1080/2162402X.2017.1349588. eCollection 2018.

PMID:
29632714
5.

A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice.

Gefen T, Castro I, Muharemagic D, Puplampu-Dove Y, Patel S, Gilboa E.

Mol Ther. 2017 Oct 4;25(10):2280-2288. doi: 10.1016/j.ymthe.2017.06.023. Epub 2017 Aug 8.

PMID:
28800954
6.

Aptamer-Targeted Attenuation of IL-2 Signaling in CD8+ T Cells Enhances Antitumor Immunity.

Rajagopalan A, Berezhnoy A, Schrand B, Puplampu-Dove Y, Gilboa E.

Mol Ther. 2017 Jan 4;25(1):54-61. doi: 10.1016/j.ymthe.2016.10.021. Epub 2017 Jan 4.

7.

Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation.

Schrand B, Verma B, Levay A, Patel S, Castro I, Benaduce AP, Brenneman R, Umland O, Yagita H, Gilboa E, Ishkanian A.

Cancer Res. 2017 Mar 15;77(6):1310-1321. doi: 10.1158/0008-5472.CAN-16-2105. Epub 2017 Jan 12.

8.

A quantum leap in cancer vaccines?

Gilboa E.

J Immunother Cancer. 2016 Dec 20;4:87. doi: 10.1186/s40425-016-0192-3. eCollection 2016. No abstract available.

9.

Adaptive smoothing based on Gaussian processes regression increases the sensitivity and specificity of fMRI data.

Strappini F, Gilboa E, Pitzalis S, Kay K, McAvoy M, Nehorai A, Snyder AZ.

Hum Brain Mapp. 2017 Mar;38(3):1438-1459. doi: 10.1002/hbm.23464. Epub 2016 Dec 10.

PMID:
27943516
10.

4-1BB Aptamer-Based Immunomodulation Enhances the Therapeutic Index of Radiation Therapy in Murine Tumor Models.

Benaduce AP, Brenneman R, Schrand B, Pollack A, Gilboa E, Ishkanian A.

Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):458-461. doi: 10.1016/j.ijrobp.2016.05.013. Epub 2016 May 21.

PMID:
27598810
11.

Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression.

Kong LY, Wei J, Fuller GN, Schrand B, Gabrusiewicz K, Zhou S, Rao G, Calin G, Gilboa E, Heimberger AB.

Oncoimmunology. 2015 Dec 21;5(5):e1117739. doi: 10.1080/2162402X.2015.1117739. eCollection 2016 May.

12.

The Human Vaccines Project: A roadmap for cancer vaccine development.

Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, Gilboa E, Hammond SA, Hershberg R, Korman AJ, Kvistborg P, Melief C, Mellman I, Palucka AK, Redchenko I, Robins H, Sallusto F, Schenkelberg T, Schoenberger S, Sosman J, Türeci Ö, Van den Eynde B, Koff W, Coukos G.

Sci Transl Med. 2016 Apr 13;8(334):334ps9. doi: 10.1126/scitranslmed.aaf0685. Review.

PMID:
27075624
13.

Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery.

Gilboa E, Berezhnoy A, Schrand B.

Cancer Immunol Res. 2015 Nov;3(11):1195-200. doi: 10.1158/2326-6066.CIR-15-0194. Review.

14.

Scaling Multidimensional Inference for Structured Gaussian Processes.

Gilboa E, Saatçi Y, Cunningham JP.

IEEE Trans Pattern Anal Mach Intell. 2015 Feb;37(2):424-36. doi: 10.1109/TPAMI.2013.192.

PMID:
26353252
15.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

16.

Reducing toxicity of 4-1BB costimulation: targeting 4-1BB ligands to the tumor stroma with bi-specific aptamer conjugates.

Schrand B, Berezhnoy A, Brenneman R, Williams A, Levay A, Gilboa E.

Oncoimmunology. 2015 Jan 9;4(3):e970918. eCollection 2015 Mar.

17.

Large scale analysis of the mutational landscape in HT-SELEX improves aptamer discovery.

Hoinka J, Berezhnoy A, Dao P, Sauna ZE, Gilboa E, Przytycka TM.

Nucleic Acids Res. 2015 Jul 13;43(12):5699-707. doi: 10.1093/nar/gkv308. Epub 2015 Apr 13.

18.

CORRIGENDUM: Separable Bilayer Microfiltration Device for Viable Label-free Enrichment of Circulating Tumour Cells.

Zhou MD, Hao S, Williams AJ, Harouaka RA, Schrand B, Rawal S, Ao Z, Brenneman R, Gilboa E, Lu B, Wang S, Zhu J, Datar R, Cote R, Tai YC, Zheng SY.

Sci Rep. 2015 Jan 27;5:7967. doi: 10.1038/srep07967. No abstract available.

19.

AptaCluster - A Method to Cluster HT-SELEX Aptamer Pools and Lessons from its Application.

Hoinka J, Berezhnoy A, Sauna ZE, Gilboa E, Przytycka TM.

Res Comput Mol Biol. 2014;8394:115-128.

20.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

Supplemental Content

Loading ...
Support Center